Investors

Recent Releases

January 15, 2026

Emergent Announces Resolution of New York Attorney General Investigation

Emergent BioSolutions has reached an agreement with the Office of the Attorney General of the State of New York (OAG) to resolve its investigation related to legacy claims regarding the company’s approval of an executive trading plan in November 2020.

January 14, 2026

Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness

Since the U.S. prescription launch of NARCAN® Nasal Spray in 2016, the medicine has been trusted as a safe, effective way to reverse opioid overdoses, and today, new solutions like the NARCAN® carrying case aims to make accessibility paramount - ‘Trusted Then. Trusted Now’ GAITHERSBURG, Md. , Jan.

January 12, 2026

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation

GAITHERSBURG, Md. , Jan. 12, 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions, Inc. (NYSE: EBS) announced it made a voluntary prepayment of $100 million under its outstanding term loan facility in late December 2025 using cash on hand. “This significant milestone reflects strong progress in